5 Student Teams' Innovations Win 2026 Collegiate Inventors Competition

ALEXANDRIA, Va., Oct. 16, 2026 /PRNewswire/ -- A glimpse into the future of American innovation and emerging technological trends from the nation's brightest young innovators — from a wearable knee rehab system to emergency resuscitation — were recognized and honored this week at the 2026 Collegiate Inventors Competition®, an annual competition for college and university students and their advisers.

Finalist teams (five Undergraduate and five Graduate), consisting of 25 students from nine colleges and universities across the United States, presented their inventions to an esteemed panel of final-round judges composed of the most influential inventors and innovation experts in the nation — National Inventors Hall of Fame® Inductees and United States Patent and Trademark Office (USPTO) officials.

"Innovation is a journey that requires creativity, courage and persistence," said National Inventors Hall of Fame Chief Executive Officer Monica Jones. "We are proud to support, recognize and reward these young inventors who embody all these traits, and to provide opportunities to meet and learn from the greatest role models in American innovation — Inductees of the National Inventors Hall of Fame."

Established in 1990, the Collegiate Inventors Competition is a program of the National Inventors Hall of Fame and is sponsored by the USPTO. In addition to cash awards, the winning teams also receive a USPTO Patent Acceleration Certificate.

FIRST-PLACE WINNERS ($10,000 PRIZE)

UNDERGRADUATE:

CPRight, University of Washington

Team Members: Shubham Bansal, Prisha Hemani, Deeya Sharma, Nikhita Vaddineni; Adviser: Tristan Jafari

Real-time guidance for emergency resuscitation: Each year, more than 350,000 Americans experience a heart attack outside a hospital, and about 90% of them die. Bystanders are often willing to help but are unable to deliver high-quality CPR. CPRight is a single-use, wallet-sized patch a rescuer places on a patient's sternum. Displaying simple LED cues, it shows the rescuer, in real time, whether compression depths and rates are effective. CPRight does not require any additional technology or equipment, making it accessible and easy to use when seconds count to save lives.

GRADUATE:

ClearView-Jaw, University of Pittsburgh School of Medicine

Team Members: William McKay, Zachary Spears, Amogh Vellore; Advisers: Anish Ghodadra, Matthew Spector

Improving outcomes for head and neck cancer patients: Head and neck cancer patients often need mandibular reconstruction after jaw tumor removal, followed by high-dose radiation. The titanium plates used to secure the reconstructed jaw can distort radiation, shielding tumor cells and scattering the radiation into healing tissue, with about 60% of patients developing a complication within five years. The ClearView-Jaw device reduces harmful backscatter and shadowing while helping clinicians target tumors more precisely, lowering complications and improving patient outcomes.

RUNNER-UP WINNERS ($5,000 PRIZE)

UNDERGRADUATE:

KAIRS (Knee Artificial Intelligence Rehabilitation Sleeve), University of North Carolina at Chapel Hill

Team Members: Samanyu Dixit, Hieu Minh Doan, Sahaj Sapovadia, Chinmay Singh; Adviser: Devin Hubbard

A smart solution for knee recovery: After knee injuries and surgeries, patients follow months-long rehabilitation routines. The Knee Artificial Intelligence Rehabilitation Sleeve (KAIRS), a wearable rehab system, continuously monitors the range of knee motion and quality of movement during at-home exercises and everyday activities on the move. With a flexible, sensor-embedded sleeve, mobile app and cloud-based machine learning model, KAIRS delivers individualized progress tracking for patients and remote monitoring for clinicians. This invention could improve rehab adherence, support clinical decisions, enable personalized care plans and expand recovery guidance to patients with limited access to physical therapy.

GRADUATE:

BioAxis, New York University

Team Members: Rayan Bargouth, Asser El Ashwah; Adviser: Richard Stein

Supporting rotator cuff healing: Partial-thickness rotator cuff tears affect about 3 million Americans annually. Standard care includes rest, rehabilitation and pain management but does not repair structural damage. Many untreated tears progress to full-thickness rupture. Developed by Vitalis Regenerative Materials Inc., BioAxis is a single-use, point-of-care medical device that combines a patient's platelet-rich plasma with a prefilled bioresorbable polymer to form a tissue-adherent hydrogel. This closed sterile system combines scaffold reconstitution, controlled platelet activation, and injectable hydrogel delivery to support tendon preservation and repair for patients who don't meet the threshold for full surgical repair.

PEOPLE'S CHOICE AWARD WINNER ($2,000 PRIZE)

NeuTrode, University of South Florida

Team Members: Bridget Clift, Cristina Ramirez-Vargas, Addison Whitehead; Adviser: Nathan Schilaty

Reliable technology for neurological care: Electroencephalography (EEG) helps diagnose and monitor neurological conditions such as epilepsy, sleep disorders and brain injuries. Current EEG technologies consist of wet, semi-dry and dry electrodes, but each presents significant limitations. Providing an innovative alternative, NeuTrode is a flexible EEG electrode designed to maintain consistent scalp contact without the use of gels or liquids. Its soft, comfortable design adapts to different hair densities, skin conditions and head shapes, and it enables faster setup, improved patient comfort and steady, reliable signal acquisition.

About the Collegiate Inventors Competition

The Collegiate Inventors Competition encourages and drives innovation and entrepreneurship at the collegiate level. A program of the National Inventors Hall of Fame, this competition recognizes and rewards the research, innovations and discoveries by college students and their advisers for projects leading to inventions that have the potential of receiving patent protection. Introduced in 1990, the competition has featured more than 500 innovators who have created cutting-edge, world-changing inventions, and awarded cash prizes to winning student teams for their innovative work and scientific achievement through the help of its sponsors. For more information,, visit invent.org/collegiate-inventors.

CONTACT:

Ken Torisky

National Inventors Hall of Fame

[email protected]

234-901-6085

SOURCE Collegiate Inventors Competition

Share this article

QUEBEC CITY, Oct. 16, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF) today provides an update on its proposed listing on the NYSE American in connection with its initial public offering in the United States (the "Offering"), as initially announced on July 27, 2026, and subsequently updated in the Company's press releases dated August 18, 2026, and September 11, 2026.

The Company remains committed to completing this initiative. Devonian continues to actively work with ThinkEquity on the preparations and necessary steps to complete the Offering and the listing of its common shares and warrants on the NYSE American under the symbols "DHGR" and "DHGR WS," respectively.

The Company will provide an update, by way of a press release, of the revised anticipated date for the commencement of trading of its securities on the NYSE American and the expected closing date of the Offering, both of which remain undetermined at this time.

The Offering and the proposed listing on the NYSE American are subject to market conditions and the receipt of required regulatory approvals, including those of the NYSE American LLC and the TSX Venture Exchange (the "TSXV"). There can be no assurance that the Offering will be completed or, if completed, as to its timing, size or final terms. The Company remains listed on the TSXV.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. No securities will be offered or sold to investors residing in Québec or elsewhere in Canada in connection with the Offering.

About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune fibroinflammatory disease with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of fibroinflammatory autoimmune diseases including but not limited to atopic dermatitis, radiodermatitis and ulcerative colitis.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Quebec, Canada where it owns a state-of-the-art extraction facility. Devonian is traded publicly on the TSXV (TSXV: GSD) and currently quoted on the OTCQB Venture Market (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com.

Forward-looking statements

All statements contained in this press release, other than statements of historical fact, including, without limitation, statements concerning the ongoing efforts to obtain the proposed listing of the Company's common shares and warrants on the NYSE American, the potential completion of the Company's initial public offering in the United States (the "Offering"), the proposed trading symbols, the required regulatory approvals, the potential dates for the commencement of trading and the closing of the Offering, and, more generally, statements included under the heading "About Devonian," constitute "forward-looking information" or "forward-looking statements" within the meaning of applicable securities laws (collectively, "forward-looking statements").

These forward-looking statements are based on the Company's current expectations, estimates and assumptions as of the date of this press release. They can generally be identified by the use of words such as "anticipates," "believes," "expects," "intends," "plans," "may," "could," "should," "will," or similar expressions, including their negative forms or grammatical variations, which indicate that certain events or outcomes may occur or be achieved.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. These risks and uncertainties include, without limitation, market conditions, the Company's ability to complete the Offering and the proposed listing on the NYSE American, obtaining the necessary regulatory approvals, including those of the NYSE American LLC and the TSX Venture Exchange (the "TSXV"), as well as uncertainties regarding the timing, size and final terms of the Offering. There can be no assurance that the Offering or the listing on the NYSE American will be completed, or that the Company's anticipated objectives and timelines will be achieved.

Forward-looking statements are provided for the purpose of informing readers of management's expectations and plans regarding the future. Readers are cautioned not to place undue reliance on these forward-looking statements, as a number of significant risk factors and future events could cause actual results to differ materially from the beliefs, plans, objectives, expectations, forecasts, estimates, assumptions and intentions expressed or implied in such forward-looking statements.

All forward-looking statements contained in this press release are expressly qualified by these cautionary statements and by the cautionary statements contained in the Company's other filings with the applicable Canadian securities regulatory authorities and under the heading "Risk Factors" in the registration statement relating to the Offering filed with the U.S. Securities and Exchange Commission (the "SEC"). The Company undertakes no obligation to update or revise any forward-looking statements or to explain any material differences between subsequent actual events and such forward-looking statements, except as required by applicable law.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Devonian Health Group Inc.

Share this article

Running on the OX and VX hardware platforms already deployed in food manufacturing, the new capability delivers up to >99%* detection accuracy at line speed, with automated response, full audit logging, and analytics through the V-CORTX platform

BEDFORD, Mass., Oct. 16, 2026 /PRNewswire/ -- Oxipital AI today announced the launch of Foreign Material Detection, a new AI vision capability that identifies contaminants in real time on high-speed food production lines. These solutions are deployed and operating in production environments today, trained on the Foreign Materials most responsible for recalls and regulatory action, and available on the same OX and VX hardware platforms food producers already use for quality inspection and process automation.

Foreign Material Detection joins quality inspection and vision-guided robotics as part of Oxipital AI's unified AI vision and intelligence platform.

"What we kept hearing from customers was that they needed a single platform that could handle quality, robotics, and food safety without adding complexity. Adding Foreign Material Detection to our platform is a direct response to that. Our customers told us they wanted fewer vendors, fewer integration headaches, and more confidence in what their inspection system could catch," said Mark Chiappetta, CEO of Oxipital AI.

SYNTHETIC DATA GENERATION GIVES CUSTOMERS A HEAD START

Rather than waiting for contamination events to build training data, Oxipital AI uses synthetic data generation to train its models on the visual signatures of the foreign materials most commonly found in food production, including hard and soft plastics, wood chips, full and partial PPE, cardboard, metal shards, bone fragments, and more. Those signatures are simulated across varied lighting conditions, product types, and line speeds. Models arrive production-ready and start inspecting on day one of deployment.

The result is detection accuracy of up to 99%* in production environments, with precision tuning that keeps false positives low. Unnecessary stoppages cost time, product, and crew attention. Oxipital AI's models are built to differentiate genuine foreign material from natural product variation, so the line keeps running when it should.

DETECTION THAT DRIVES ACTION, NOT JUST ALERTS

When a contaminant is detected, the system does not stop at simply flagging it to the user. V-CORTX integrates with existing line control systems to trigger automated responses based on severity classification. A minor anomaly can slow the line. A confirmed high-severity event stops it. No manual intervention, no delay.

The system also identifies the type of contaminant detected, not just its presence. That classification gives quality assurance and engineering teams the information needed to trace where a foreign material was introduced, whether it is a worn line component, a supplier issue, or a changeover gap.

A FULL AUDIT TRAIL COMPLETE WITH ANALYTICS

Every foreign material event is logged automatically in the V-CORTX analytics dashboard, with timestamp, classification, imagery, dimensional data, and throughput impact. Plant managers and corporate engineering teams get a continuous, searchable record that supports FSQA documentation, and root cause analysis giving them the tools they need to keep production running safely.

DEPLOYED AND RUNNING TODAY

Foreign Material Detection from Oxipital AI is operating on production lines in the food industry right now. Food and beverage manufacturers can see it running live at Pack Expo at the Oxipital AI booth S-3192 from October 18th to the 21st.

ABOUT OXIPITAL AI

Oxipital AI is a unified AI vision and intelligence platform for food and industrial manufacturing, bringing together quality inspection, foreign material detection, and vision-guided robotics. Built on the OX and VX hardware platforms, its technology gives producers one system to inspect, protect, and automate their lines. Spun out of Soft Robotics, Oxipital AI is deployed across production lines at some of the world's largest food producers. Learn more at www.OxipitalAI.com.

MEDIA CONTACT

Drishti Shah

[email protected]

* Vision-based inspection can only detect foreign material that is visible to the camera. Items that are too small to resolve at operating line speed, or that are not presented to the camera's field of view, may not be detected.

SOURCE Oxipital AI Inc.

Share this article

SAN ANTONIO, Oct. 16, 2026 /PRNewswire/ -- PayrollOrg® will bring together payroll professionals from colleges and universities nationwide for its 39th Annual Educational Institutions Payroll Conference (EIPC), October 18–21, 2026, in Columbus, Ohio. The conference will focus on emerging technologies, legislative developments, and financial compliance issues affecting higher education institutions.

"As regulations evolve and artificial intelligence (AI) reshapes the workplace, higher education payroll teams can't afford to fall behind," said Dan Maddux, Executive Director of PayrollOrg. "EIPC gives them the knowledge and tools to stay ahead of these changes."

This year's conference will feature sessions addressing AI in payroll, federal and state legislative developments, payroll and data governance, nonresident alien taxation, and IRS fringe benefit regulations specific to higher education. Additional workshops explore faculty contracts, student employment, payroll security, fraud prevention, and strategies for improving operational efficiency.

Featured general sessions include "Payroll Like a Boss," presented by John Bernatovicz, founder and president of Willory LLC; a legislative update from PayrollOrg's government relations team; and a closing session examining payroll, data, and AI governance.

The conference will take place at the Hyatt Regency Columbus, with on-site registration beginning Sunday, October 18, at 1 pm ET. The event is sponsored by Sprintax.

For more information about the conference, visit Payroll.org/EIPC or view the Program Brochure.

About PayrollOrg

PayrollOrg (PAYO) is the leading global authority in payroll education, publications, and professional development. As the only organization delivering truly borderless payroll compliance and payroll management training, PAYO equips payroll professionals, strategic leaders, and organizations to meet the evolving demands of a global workforce.

SOURCE PayrollOrg

Share this article

AI Gamechangers recognition highlights Zifo's practical application of artificial intelligence to accelerate master data creation for lab systems

CHENNAI, India, Oct. 16, 2026 /PRNewswire/ -- Zifo, a leading global enabler of AI and data-driven enterprise informatics for science-driven organizations, has been recognized as a Gamechanger in Healthcare & Pharma in the enterprise segment at the Nasscom AI Gamechangers Awards 2026 for its innovative application of AI to laboratory master data creation.

The AI Gamechangers program spotlights impactful AI implementations emerging from India's innovation ecosystem. Zifo's recognition highlights its AI-based service accelerator for accelerating the creation of master data for laboratory information management systems, or LIMS.

Addressing a Critical Laboratory Data Challenge

Reliable master data is foundational to the successful configuration and implementation of a LIMS. In lab environments, however, the information required to create this master data can be distributed across PDFs, specifications, procedures, spreadsheets, and other source documents.

Identifying the relevant information, reviewing it for accuracy, and converting it into structured master data objects can require significant manual effort. The process must also support the consistency, traceability, and auditability expected in regulated environments.

Zifo applies AI-assisted automation to accelerate this work. The service accelerator extracts relevant information from laboratory source documents, organizes it into structured data, and supports the creation of master data objects for LIMS platforms.

By bringing document extraction, human review, and object creation into a more connected workflow, the AI service accelerator helps reduce the manual burden associated with LIMS configuration and implementation. It also helps in performing the verification of the objects configured and helps in validating the set up by logging a sample and generating the appropriate Report (Analysis Report of Certificate of analysis). The service accelerator is designed to improve efficiency while preserving the controls and expert oversight required for regulated laboratory operations.

Combining AI-Assisted Automation with Expert Review

Zifo's effort to lessen the burden on master data management reflects the company's practical approach to AI: applying the technology to a clearly defined operational challenge while keeping laboratory and informatics specialists in control of review and decision-making.

Rather than replacing lab expertise, the service accelerator assists implementation teams by automating document-intensive activities and presenting structured information for expert review. This approach helps teams work more efficiently while retaining transparency over how information is extracted, reviewed, and transformed into LIMS master data.

"This recognition from Nasscom reflects our focus on translating AI innovation into practical value for regulated laboratories," said Narasimhan Aravumudan, Zifo's Vice President - Scientific Data for AI and a renowned LIMS and AI expert. "The creation of accurate and reliable master data is critical to a successful LIMS implementation, but preparing this data can involve considerable manual effort. With this master data service accelerator, we are bringing AI-assisted automation, and expert review together to help laboratories receive system-ready master data more efficiently and confidently."

Advancing Practical AI for Science-Driven Organizations

The recognition reinforces Zifo's commitment to developing AI-enabled service accelerators -- dubbed as Practical AI3 -- that address real-world challenges across the scientific enterprise. Zifo combines AI with scientific, regulatory, data, and enterprise informatics expertise to help organizations improve productivity and accelerate digital transformation. https://zifo.com/practical-ai-blueprints/

For laboratories, master data creation is more than an administrative activity. Master data provides the foundation for laboratory workflows, system configurations, analytical processes, and data integrity controls. Improving how this information is prepared and reviewed can help organizations reduce implementation effort and move more efficiently toward the productive use of their LIMS platforms.

The Nasscom recognition reflects a broader industry shift from AI experimentation toward practical implementations that address defined operational challenges and deliver measurable value.

Through broader portfolio of AI-enabled service accelerators, Zifo continues to help science-driven organizations adopt AI in ways that are practical, governed, and aligned with the requirements of regulated operations.

About Zifo

Zifo is a leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, Zifo serves industries including pharmaceutical, biotechnology, chemicals, food and beverage, oil and gas, and FMCG. Trusted by more than 190 science-focused organizations worldwide, Zifo helps its customers advance digital scientific innovation. https://zifo.com

About Nasscom AI Gamechangers

Nasscom AI Gamechangers was launched in 2021 to spotlight transformative AI implementation stories across India's innovation ecosystem. The program recognizes solutions that demonstrate real-world impact, reshape industries, and address critical socioeconomic and operational challenges. Its sector-specific award categories include Healthcare & Pharma, Manufacturing, Banking, Financial Services & Insurance, Energy & Utilities, Retail & Consumer Packaged Goods, and Technology, Media & Telecom. https://Nasscom.in/ai-gamechangers/

SOURCE Zifo

Share this article

SALT LAKE CITY, Oct. 16, 2026 /PRNewswire/ -- FatPipe, Inc. (NASDAQ: FATN) ("FatPipe" or the "Company"), a pioneer in enterprise-class software-defined wide area networking, cybersecurity and network observability solutions, is pleased to announce that it will host an investor webinar to present its financial results for the second quarter of fiscal year 2027.

The investor webinar will be held on November 4, 2026, from 4:30 PM to 5:00 PM Eastern Time. Senior management will review the Company's Q2 financial performance and provide business updates, followed by a brief question-and-answer session.

Event Details

Date: November 4, 2026

Time: 4:30 PM to 5:00 PM ET

Format: Investor webinar

Registration details and access information can be found here and will be made available on the Company's investor relations channels.

Registration Link: https://events.teams.microsoft.com/event/b22a6837-3591-42b5-9333-afaa81e42fd4@51ec01b9-4755-406d-a5cf-be0d14b56e66

Forward-Looking Statements

Certain statements contained in this press release, including statements relating to the Company's expectations regarding its financial performance, business outlook, and future operations, may constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements can generally be identified by the use of forward-looking terminology such as "may," "will," "expect," "intend," "anticipate," "estimate," "believe," or "continue," or other similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based on management's current expectations and are subject to various risks, uncertainties, assumptions, and changes in circumstances that are difficult to predict. These risks and uncertainties include those described in FatPipe's filings with the Securities and Exchange Commission, including its registration statement on Form S-1, as amended from time to time. Except as required by law, FatPipe expressly disclaims any obligation to update or revise forward-looking statements.

About FatPipe, Inc.

FatPipe pioneered the concept of software-defined wide area networking and hybrid WAN technology that eliminates the need for cooperation from internet service providers and enables enterprises and service providers to control multi-link network traffic. FatPipe offers a single-stack networking and cybersecurity platform designed for highly distributed, mission-critical environments. FatPipe Constellation, the AI-assisted network observability software, provides full visibility for network managers. The Company holds 13 U.S. patents related to multipath and software-defined networking technologies, and its products are sold through more than 200 resellers worldwide.

For more information, please visit www.fatpipeinc.com.

Follow us on X at @FatPipe_Inc.

Investor and Media Contacts

Email: [email protected]

Phone: +1 801.683-5656 x1140

SOURCE FatPipe Networks

Share this article

Presented by MoonPay and Venice, the inaugural Lumara Film Festival festival received more than 700 submissions from filmmakers worldwide and today reveals six finalists competing for the Grand Prize and Jury Selection, with winners announced live at the World Premiere at the Roxy Hotel Cinema in New York on October 26. The evening will also feature an exclusive extended prologue of jury member and AI filmmaker Gossip Goblin's new film "Gods Don't Give Gifts.", the first-ever AI film slated for a wide theatrical release at the end of this year.

NEW YORK, Oct. 16, 2026 /PRNewswire/ -- Lumara Film Festival, an independent film festival for the artists defining a new era of filmmaking, presented by MoonPay and Venice, has announced the six finalists competing for its Grand Prize and Jury Selection awards and the 16 nominees for its five category awards.

Lumara was created to find and celebrate the films coming out of a transformative moment for cinema. AI has given filmmakers a new set of tools and a new creative language that opens the door to opportunities otherwise unavailable to many. Submissions were open from July 24 to September 15 and drew more than 700 films. Entry was free and open worldwide, and filmmakers could use any AI filmmaking platform available.

Films were evaluated by a jury of the world's leading AI filmmakers and internet-culture figures including Voidstomper, Gossip Goblin, Chris White (executive producer, A24's "Backrooms"), JBoogxCreative, Heavy Pulp, SÜNDERMANN, BLVCKL!GHT, Ansem and FaZe Banks. Films were judged on the strength of the idea, the quality of the storytelling, and how well the filmmaker used AI.

The six finalists will now move into competition for the Grand Prize of $32,000 and 3.2 million Venice AI credits and the Jury Selection award of $20,000 and 2 million Venice AI credits.

The finalists are:

- "Black Thunder" (Ryan Lightbourn)

- "Candy" (Jiaze Li)

- "Gabriel" (T Zhang)

- "Killabears – The Broadcast" (Mikael Tyrsen)

- "Living with a Merman" (Chris Capel)

- "Mianmian" (Yingjie Chen)

This year's categories and their nominees include:

- Terminal Award (best experimental film), $12,000 and 1.2 million Venice AI credits

- "REVIVER" (Aleksey Dor)

- "Stories My Great Great Great Grandmother Told Me" (Philippe Noguchi)

- "THE LAST TRIBE" (Stephane Benini)

- Serenissima Award (best film made with Venice), $12,000 and 1.2 million Venice AI credits

- "Black Thunder" (Ryan Lightbourn)

- "Er Loop" (Marco Magario)

- "Never Forget" (Allan Ecax)

- Get Shorty Award (best film under two minutes), $8,000 and 800,000 Venice AI credits

- "Ato de [Later]" (Luke Mazey)

- "COMPULSION" (Gyuseon Lee)

- "Do Not Disturb" (Adrian Daniel Botnariu)

- "Summer Afternoon, July 1994" (Charlie Park)

- Mouse Award (best film for children or young adults), $8,000 and 800,000 Venice AI credits

- "Far away home" (Siping Song)

- "FIX" (Eunha Lee, Sora Lee and Hakhoon Lee)

- "Roraima" (Ishan Devare Modi)

- Rekt Award (best satire, comedy or musical about finance, markets or crypto), $8,000 and 800,000 Venice AI credits

- "Great Pepe Wars" (Aiden Guo)

- "JUST SAY SOLANA" (Yassine Le Gall)

- "ROLL EVERYTHING" (Ashanth Phillips)

The winner of each category award will be announced on the Venice and MoonPay channels.

The finalists will be screened in full at the inaugural Lumara screening and awards night taking place on October 26 at the Roxy Hotel Cinema in New York City, with winners announced at the event.

The evening will also include screenings of the category-winning films, and new work previews from members of the jury, including an exclusive an exclusive extended prologue of Gossip Goblin's new film God's Don't Give Gifts, the first AI film slated for a wide theatrical release at the end of this year.

The winning films will premiere online on X and YouTube on October 27.

About MoonPay

MoonPay is a global financial technology company that provides infrastructure for moving value across traditional and digital financial systems. Founded in 2019, MoonPay serves more than 35 million customers in 180 countries and more than 1500 enterprise clients across crypto and fintech. Its products support payments, trading, commerce, stablecoin infrastructure and other services that connect conventional payment networks with blockchain-based financial rails. MoonPay maintains regulatory licenses and authorizations in multiple jurisdictions, including the United States and European Union. For more information, visit www.moonpay.com.

About Venice

Venice is a privacy-first AI platform built for unlimited creative freedom. It gives filmmakers unrestricted access to the world's leading video, image and audio models in one private workspace, alongside frontier text and code models, without censorship and without surveillance. Trusted by 5 million users, Venice runs leading video models including Seedance 2.5, image models from OpenAI, Google and xAI, and voice and music generation, so a filmmaker can make the story exactly as they envision it, rather than the one a platform allows. Venice is accessible through its app and API. Learn more at venice.ai.

Media Contacts

MoonPay

[email protected]

Venice

[email protected]

Press passes available upon request.

SOURCE MoonPay

Share this article

Behavioral data veteran joins as AI raises the value of real consumer signals

IRVINE, Calif., Oct. 16, 2026 /PRNewswire/ -- MFour Data Research, provider of the largest, first-party mobile-app consumer panel in the U.S. and the only platform connecting surveys and behaviors for full journey intelligence from ChatGPT to checkout, today named Sean Miller Vice President, First-Party Data Engineering, reporting to Chief Technology Officer Aaron Wepler. Miller will lead engineering for all of MFour's first-party data, which consumers share through transparent consent. That data includes purchases and receipts, app usage, web browsing, location and store visits, desktop activity and LLM conversations, all connected to each consumer's own survey answers.

The appointment puts data at the center of MFour's business. As AI models and synthetic audiences multiply, credible insight depends on real, permissioned human data. Miller's mandate is to bring MFour's entire engineering stack in-house, from data collection through the company's own AI model. AI now makes that work possible in days, not months. The foundation won't change: behavioral and survey data collected with transparent consent and combined on a single platform. Through its Fair Trade Data® model, MFour compensates members of its 13M+ opted-in panel for the data they share. This approach connects multiple behavior channels back to the same consumer, so brands and researchers can get a full picture of what consumers do across the entire journey and even survey them to understand why.

Miller brings more than 16 years of experience building behavioral data products and panels. He was most recently Senior Executive Vice President, Operations at Luth Research.

"The race to understand the consumer journey will be won with real human data behind synthetic models, not the fraudulent data too much of this industry turns a blind eye to," said Chris St. Hilaire, Founder and CEO of MFour. "And consent can't be buried in fine print. People should know exactly what they're sharing and get paid for it. That's transparent consent, and it's the only ethical way to build this business. Validated, connected, and constantly calibrated data is the key to instant insights on demand. Sean has spent his career building exactly that kind of data."

"Sean knows behavioral data from collection to client deliverable," said Wepler. "He brings the discipline to grow our first-party data with quality we can measure, not just assert."

"I've spent my career building behavioral data, and I've never seen a foundation like MFour's: real people, real behavior and real survey answers, all collected with transparent consent and connected in one place," said Miller. "My job is to give clients data they can trust the moment they see it and to make sure panelists always know exactly what they're sharing."

About MFour

MFour Data Research, founded in 2011, provides validated, opt-in consumer behavior and survey data powered by its Surveys On The Go® app and Fair Trade Data® model. The company's 13M+ consumer panel generates nine deterministic data streams — ChatGPT conversations, location, app usage, web browsing, receipts, demographics, attitudes, survey responses and behavior-triggered surveys — all connected to a single identity.

Through MFour Studio™, organizations can access these behavioral and survey signals to understand consumer journeys and measure outcomes, with DANI™ (Data Analytics Navigation Instructor), MFour's AI assistant, providing on-demand analysis across 4 billion monthly buyer signals. MFour is trusted by Samsung, Google, Amazon Ads, Microsoft, Hulu, Keurig Dr Pepper, Papa Johns and hundreds of other global brands.

Full Journey Intelligence. Know What to Do Next.

Learn more at MFour.com.

SOURCE MFour Data Research

Share this article

LONDON, Oct. 16, 2026 /PRNewswire/ -- The "ADHD Drugs Market – Growth, Share, Opportunities & Competitive Analysis, 2025–2035" report has been added to the Credence Research Inc. market intelligence offering.

The global adhd drugs market was valued at USD 14.11 billion in 2025. Revenue is projected to reach USD 22.79 billion by 2035, representing a compound annual growth rate (CAGR) of 4.91% over the 2025–2035 market-value interval. North America held the largest regional share at 60.0% in 2025, while Asia Pacific is expected to record the fastest growth at 6.34% annually. These revenue forecasts and market shares are Credence Research estimates.

Key Takeaways

- The market increases from USD 14.11 billion in 2025 to USD 22.79 billion in 2035 at a stated 4.91% CAGR.

- North America contributed 60.0% of global 2025 value; Asia Pacific has the highest modeled regional growth rate at 6.34%.

- Methylphenidate represented 30.0% of drug-type revenue in 2025.

- Children and adolescents represented 56.0% of patient demographic value in 2025.

- Retail pharmacies represented 68.0% of channel revenue in 2025.

Scope & Segmentation - ADHD Drugs Market

Prescription drugs approved for attention-deficit/hyperactivity disorder in adults and children, including amphetamines, methylphenidate, lisdexamfetamine, atomoxetine, guanfacine, clonidine and newer agents. Behavioral therapy, diagnostic services, supplements and digital therapeutics are excluded from pharmaceutical revenue.

- By drug type: Amphetamines; Methylphenidate; Lisdexamfetamine; Dexmethylphenidate; Atomoxetine; Guanfacine; Clonidine; Others.

- By demographics: Children and adolescents; Adults.

- By distribution channel: Hospital pharmacies; Retail pharmacies; Online pharmacies; Others.

- By geography: North America; Europe; Asia Pacific; Latin America; Middle East and Africa.

Download sample and detailed segmentation: https://www.credenceresearch.com/report/adhd-drugs-market

Why This Report Matters

- Maps the commercial drivers of this market without treating forecasts as verified transaction totals.

- Separates leading applications and products from the regional opportunities and access constraints that affect revenue.

- Assesses supplier competition, recent regulatory or product developments and likely implications for business planning.

Market Overview

ADHD prescribing involves long-term decisions about efficacy, tolerability, dose scheduling and medication availability. Stimulants remain central to clinical practice, but alternatives are important for patients who cannot tolerate them or prefer different mechanisms.

Growing recognition of ADHD in adults is expanding the potential treated population. At the same time, generic versions of established stimulants reduce average prices, while new extended-release and nonstimulant medicines seek a premium based on delivery convenience or clinical differentiation.

Market Insights

- Methylphenidate represented 30.0% of 2025 drug-type value, supported by extended-release brands and generics.

- Children and adolescents accounted for 56.0% of demographic revenue, while adults represent the faster-growing patient group.

- Retail pharmacies generated 68.0% of channel value, while online fulfillment grows from a smaller base under controlled-substance rules.

Key Attributes

Market Segmentation

By drug type

Amphetamines; Methylphenidate; Lisdexamfetamine; Dexmethylphenidate; Atomoxetine; Guanfacine; Clonidine; Others

By demographics

Children and adolescents; Adults

By distribution channel

Hospital pharmacies; Retail pharmacies; Online pharmacies; Others

Market Drivers

Expanded diagnosis of ADHD in adulthood

Adult assessment and specialty mental health services have expanded the identified patient population. Patients diagnosed later in life often need treatment that supports both work and home functioning, which can lengthen the duration of medicine use. Demand still depends on clinical evaluation and continued access to appropriate prescribing.

Demand for differentiated dosing and nonstimulant options

Once-daily formulations, nighttime dosing and pediatric-friendly suspensions address adherence and dosing difficulties. New therapies can offer choices for people with poor response or intolerance to current products, though clinical evidence, safety labeling and reimbursement decisions determine uptake.

Market Trends and Opportunities

New mechanisms are entering an established market. Otsuka announced U.S. approval of Simtriyo (centanafadine) in July 2026 for eligible adults and children aged 6 and older, introducing a triple reuptake inhibitor.

Increased generic lisdexamfetamine availability has intensified competition for established branded stimulants. Differentiated long-acting products and reliable manufacturing may gain share where shortages limit routine prescribing.

Regional Analysis

Credence Research estimates the following 2025 revenue shares. All five regional figures are proprietary research-model allocations rather than independently audited sales totals.

North America | 60.0% share in 2025

The United States has high levels of diagnosis and branded extended-release pricing, while supply quotas and generic competition affect pharmacy availability and sales.

Europe | 20.0% share in 2025

Adult diagnosis and specialist services are expanding, but reimbursement systems and lower net medicine prices restrain value per patient.

Asia Pacific | 13.0% share in 2025

Japan, Australia and increasingly China support the fastest growth at 6.34%, reflecting better recognition and access from a comparatively small revenue base.

Latin America | 4.0% share in 2025

Methylphenidate dominates access in many countries, while specialist capacity, insurance and import controls affect uptake of newer products.

Middle East and Africa | 3.0% share in 2025

Gulf states are expanding pediatric mental health infrastructure, but affordability and diagnosis gaps limit treatment in many other countries.

Market Challenges

Stimulant production is subject to controlled-substance quotas, and periodic shortages can prevent patients from filling prescriptions. Suppliers must coordinate authorized active ingredient supply and local distribution while maintaining regulatory compliance.

Potential adverse effects and risks of misuse require ongoing clinical monitoring. In June 2025, the FDA required expanded warnings on weight loss risk with extended-release stimulants in children younger than six, an age group for which those products are not approved.

Future Outlook

The 2035 outlook rests on growth in adult diagnosis, availability of new treatment classes and wider use of differentiated delivery formats. Generic competition is likely to restrain market revenue per prescription.

Manufacturers with resilient supply chains, evidence-backed formulations and good payer access may be better positioned than suppliers dependent on a single legacy stimulant brand.

Competitive Landscape

Takeda, Johnson & Johnson and Novartis have important legacy stimulant franchises, with generic competitors challenging brand share. Supernus competes in nonstimulants and Otsuka has introduced a new triple reuptake inhibitor.

Tris Pharma, Collegium and other specialty firms concentrate on differentiated formulations. Generic manufacturers compete on price and reliable access to controlled active ingredients, which can be decisive when pharmacies experience shortages.

Key Players

- Takeda; Johnson & Johnson; Novartis; Otsuka Pharmaceutical

- Supernus Pharmaceuticals; Tris Pharma; Collegium Pharmaceutical; Lupin

- Mallinckrodt; Aytu BioPharma

Report Coverage

- Quantitative market size and CAGR through 2035, with base-year segmentation, regional shares and technology or product trends.

- Demand drivers, competition, market restraints, policy and reimbursement where relevant, and primary supplier dynamics.

- Recent industry events supported by original regulator or company sources.

- Credence Research forecasts, shares and segment models are proprietary estimates; they are not independently audited figures.

Read the complete report and request a customized study: https://www.credenceresearch.com/report/adhd-drugs-market

Related Reports

About Us

Credence Research Inc. is a global market intelligence and consulting firm founded in 2015. The company provides quantitative industry research, competitive analysis and strategic advisory services to organizations assessing market opportunities and investment decisions. Its reports combine primary and secondary research to evaluate market size, segmentation, growth drivers, emerging technologies and regional commercial conditions.

Credence Research serves business leaders, investors, governments, nonprofits and other stakeholders across industries, with research deliverables designed to inform product planning, market entry and competitive positioning.

Contact Us

Credence Research Inc.

Tower C-1105, S 25, Akash Tower

Vishal Nagar, Pimple Nilakh, Haveli

Pune - 411027, India

Europe Phone: +44 7453 598 606

US Phone: +1 6282 627 656

Email: [email protected]

Website: www.credenceresearch.com 

SOURCE Credence Research Inc.

Share this article

DELRAY BEACH, Fla., Oct. 16, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the global Causal AI Market is estimated at USD 158.7 million in 2026 and is projected to reach USD 761.4 million by 2031, registering a 36.8% CAGR during 2026–2031.

Browse 300 market data Tables and 50 Figures spread through 350 Pages and in-depth TOC on "Causal AI Market - Global Forecast to 2031"

Causal AI Market Size & Forecast:

- Market Size Available for Years: 2021–2031

- 2025 Market Size: USD 110.7 million

- 2026 Market Size: USD 158.7 million

- 2031 Projected Market Size: USD 761.4 million

- CAGR (2026–2031): 36.8%

Causal AI Market Trends & Insights:

- Growth is being supported by demand for causal discovery, causal inference, counterfactual analysis, root-cause diagnosis, experimentation, and decision optimization across financial services, life sciences, marketing, industrial operations, and enterprise planning.

- Software is estimated to account for 77.8% of the Causal AI Market in 2026

- The decision intelligence & scenario planning segment is expected to register the fastest growth of 42.4% CAGR between 2026 and 2031

- The healthcare, pharma & life sciences segment is expected to be the fastest-growing segment across the forecast period

- North America is estimated to account for the largest regional share of 37.1% in 2026

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162494083

Rising enterprise demand for AI systems that can determine why outcomes occur, estimate intervention impacts, compare alternative actions, and support decisions amid changing business conditions is driving growth. Organizations are increasingly using causal discovery, treatment-effect estimation, counterfactual analysis, root-cause diagnosis, experimentation, and decision optimization to complement conventional predictive analytics. Adoption is expanding across life sciences, financial services, marketing, industrial operations, and enterprise planning. Integrating Causal AI with generative AI, agentic AI, digital twins, and automated experimentation is further accelerating commercialization by embedding causal reasoning directly into recurring operational and strategic workflows, rather than confining it to specialist data-science projects.

Software is becoming the primary layer for operationalizing causal reasoning at enterprise scale.

Software is expected to account for the largest share of the Causal AI Market in 2026, supported by rising adoption of platforms and point solutions that combine causal discovery, inference, simulation, experimentation, and decision optimization within reusable enterprise environments. Organizations are increasingly moving away from isolated causal modeling projects toward software that can connect with existing data estates, support multiple decision workflows, and make causal analysis accessible to business users. Broad Causal AI platforms are expanding into counterfactual simulation, intervention analysis, optimization, and agentic execution, while point solutions are gaining adoption in focused areas such as life sciences, marketing measurement, IT operations, and industrial analytics. This transition toward production-grade software is strengthening recurring revenue opportunities, increasing deployment scale, and enabling causal capabilities to become part of day-to-day enterprise decision processes rather than one-time analytical engagements.

Request for Proposal: https://www.marketsandmarkets.com/requestsampleNew.asp?id=162494083

Decision Intelligence & Scenario Planning is emerging as the strongest growth avenue for action-oriented Causal AI.

Decision intelligence & scenario planning is expected to be the fastest-growing application segment during the forecast period, as organizations increasingly seek to understand the likely consequences of alternative actions before committing capital or operational resources. The segment includes business-driver analysis, what-if modeling, counterfactual simulation, intervention-impact assessment, and resource-allocation optimization. Causal AI enables enterprises to move beyond forecasting what may happen toward estimating what could happen if controllable variables such as pricing, investment, promotions, capacity, or operating policies are changed. This is expanding adoption across strategic planning, commercial decision-making, capital allocation, and operational optimization. Vendors are consequently developing simulation-led environments that allow decision-makers to compare multiple courses of action, quantify potential trade-offs, and select interventions more closely aligned with desired business outcomes under changing market and operating conditions.

North America combines vendor concentration, enterprise AI maturity, and high-value causal use cases.

North America is expected to account for the largest share of the Causal AI Market in 2026, supported by a mature enterprise AI ecosystem, strong availability of advanced analytics talent, and high adoption of data-driven decision technologies across major industries. The region has particularly strong commercial activity in pharmaceutical research, marketing measurement, enterprise decision intelligence, explainable AI, and experimentation, where causal approaches are increasingly being integrated into production workflows. North America also hosts several prominent vendors, including Aitia, Alembic, LiftLab, Measured, Lifesight, and Howso, covering areas such as life sciences digital twins, enterprise causal intelligence, incrementality measurement, and understandable AI. High technology spending among pharmaceutical, financial services, retail, consumer goods, and technology companies, combined with an established ecosystem of data providers, cloud platforms, consulting firms, and AI developers, is expected to sustain the region's market leadership.

Request Pricing: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=162494083

Top Companies in Causal AI Market:

The Top Companies in Causal AI Market are causaLens (UK), Aitia (US), Alembic (US), LiftLab (US), Prophet (Australia), Measured (US), Causaly (UK), Lifesight (US), Causify (US), and Howso (US). These vendors illustrate the different commercialization models emerging across the market, ranging from horizontal Causal AI platforms and enterprise decision-intelligence systems to life sciences digital twins, scientific intelligence, marketing incrementality, scenario simulation, and explainable AI. Competitive differentiation is increasingly determined by the ability to operationalize causal reasoning within existing enterprise workflows, integrate with data and AI environments, support domain-specific decision processes, and demonstrate measurable business outcomes. Vendors that combine proprietary causal technology with strong implementation capabilities, domain expertise, enterprise integrations, and repeatable applications are better positioned to expand contract values and move from departmental deployments toward broader enterprise adoption as the market matures.

Causal AI Market - Investment & funding +Merger & Acquisition

Investment Funding Context

Investment activity in the Causal AI Market is increasingly concentrating on vendors that can convert causal models into scalable enterprise decision systems rather than offering causal analysis as a standalone data-science capability. Capital is being directed toward real-time decision intelligence, causal simulation, domain-specific applications, and infrastructure capable of operationalizing causal reasoning at enterprise scale. In November 2025, Alembic raised USD 145 million in Series B and growth financing, led by Prysm Capital and Accenture, with participation from WndrCo, NextEquity, Silver Lake Waterman, Liquid 2 Ventures, and other investors. The financing is supporting expansion of its Causal AI research and high-performance computing infrastructure for enterprise intelligence.

Funding is also reaching smaller Causal AI specialists targeting operational decision-making. In September 2025, Causify raised an additional USD 2.2 million in seed capital to expand its enterprise causal decision-intelligence platform across financial services, energy, supply chain, and industrial applications. FireAI has similarly raised multiple early-stage rounds since 2025 to develop its causal decision-intelligence capabilities, including Causal Chain analysis, enterprise data integration, and conversational analytics. Public funding records indicate cumulative funding of more than USD 1.4 million by July 2026. These investments show a two-tier funding pattern: substantial capital is supporting the infrastructure and commercial expansion of established platforms, while smaller rounds are financing application-focused entrants seeking to embed causal reasoning into specific enterprise workflows.

Revenue Shift Context

Revenue generation in the Causal AI Market is progressively shifting from individual causal modeling projects toward recurring software platforms, decision-intelligence systems, and application-specific point solutions. The market is estimated to increase from USD 158.7 million in 2026 to USD 761.4 million by 2031, at a CAGR of 36.8%. As deployments mature, commercial value is moving beyond causal discovery and model development toward counterfactual simulation, intervention analysis, decision optimization, automated experimentation, and recurring operational workflows. This favors vendors that can integrate causal reasoning directly into existing business systems rather than require enterprises to build bespoke causal models for each use case. Two monetization models are becoming increasingly visible. Broad platform vendors are expanding revenue through enterprise-wide deployments that support multiple functions and integrate causal reasoning with agents, knowledge systems, and workflow automation.